By Debdeep Gupta | 05 Sep, 2025
Stocks to Watch Today: Biocon, Zydus Life, Indo Tech Transformers, Bharat Forge, Yasho Industries, RPP Infra Projects in focus on 05 September
Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, acquisitions, and appointments, here’s a quick look at which stocks will be in focus in today's trade:Results TodaySpiceJet, Prabhat Technologies (India), Toyam Sports, and Sanmitra Commercial will release their quarterly earnings on September 5.Stocks to WatchBioconThe US Food and D...
Live Comments
BestStockChoice01 2025-06-04 16:20:41
board review will take 5 months to decide on reverse merger of biocon biologic and biocon or if they should proceed with ipo of BBL . thats why share is not moving .
Login & Reply Like(0) Dislike(0) Repost SpamBestStockChoice01 2025-04-24 12:34:08
The Board has given its approval to raise up to ₹4,500 crore through the issuance of equity shares, non-convertible debentures with warrants, via methods such as qualified institutional placements, rights issues, preferential allotments, or private placements, in one or more tranches.
Login & Reply Like(0) Dislike(0) Repost SpamArvind01 2025-04-05 13:45:58
India has lower tariff than China. so higher sales and profit for Indian companies are possible
Login & Reply Like(0) Dislike(0) Repost Spamanbillion 2025-03-11 09:06:34
Biocon Biologics, a subsidiary of Biocon Ltd, has reported successful results of a pivotal Phase 3 study in adult patients with moderate to severe chronic plaque psoriasis (PsO).
Login & Reply Like(0) Dislike(0) Repost SpamOptionsTrade 2025-03-07 09:33:53
Biotechnology firm said its arm Biocon Biologics Ltd has entered into a strategic collaboration with Civica Inc, a not-for-profit pharmaceutical company, to enhance the accessibility and affordability of insulin aspart in the United States. Civica, founded in 2018, focuses on addressing life-saving drug shortages and reducing costs for essential medications.
Login & Reply Like(0) Dislike(0) Repost SpamOptionsTrade 2025-03-07 09:21:09
Biocon Biologics, a subsidiary of Biocon, has partnered with Civica, Inc. to improve access to affordable Insulin Aspart in the US. Civica will handle commercialisation in the US following development and clinical trials. BBL will supply Insulin Aspart drug substance to Civica, Inc., which will manufacture the finished drug product at its facility in Petersburg, Virginia.
Login & Reply Like(0) Dislike(0) Repost Spamanbillion 2025-03-05 15:22:18
Biocon in the biotech space has secured the final nod from USFDA for its Lenalidomide capsules in multiple strengths. Used to treat multiple myeloma, lymphoma and myelodysplastic syndromes. In addition, Biocon Pharma, an affiliate, has obtained USFDA approvals for Dasatinib tablets and a tentative clearance for Rivaroxaban tablets.
Login & Reply Like(0) Dislike(0) Repost SpamArvind01 2025-02-25 10:57:11
Biocon Biologics, a subsidiary of Biocon, introduced Yesintek Biosimilar in the U.S. for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
Login & Reply Like(0) Dislike(0) Repost Spamblogist01 2025-01-31 11:24:44
Biocon’s Q3FY25 performance aligned with expectations but was impacted by one-time gains recorded in Q3FY24. Last year’s earnings included revenue from the Branded Formulations India (BFI) business, which has since been divested, as well as income from the partial divestment of Biocon Biologics and a stake dilution in Bicara Therapeutics. EBITDA for the quarter rose 16 percent YoY to ₹787 crore.
Login & Reply Like(0) Dislike(0) Repost SpamDEBT_FREE 2024-12-02 15:48:39
Biocon shares are expected to gain attention after the USFDA approved YESINTEK, a monoclonal antibody developed by its subsidiary, Biocon Biologics.
Login & Reply Like(0) Dislike(0) Repost SpamBestStockChoice01 2024-10-08 12:30:17
this is fraud company... showing true colors pumped and now dumping....
Login & Reply Like(0) Dislike(0) Repost SpamTechyInvestor01 2024-09-26 16:15:25
Biocon Biologics, a subsidiary of Biocon, announced positive results from Phase-III clinical trials for its biosimilars of adalimumab and ustekinumab at the EADV Congress 2024.
Login & Reply Like(0) Dislike(0) Repost SpamArvind01 2024-09-17 14:08:00
Attention option call traders it will go into ban today and will not come out of ban till the expiry all the best for the people who are dreaming to 400 450 600 and 1000 than any other stock I know Biocon very well actually they can ban listing Biocon in stock market itself atleast retail investors will not loose their hard earned money
Login & Reply Like(0) Dislike(0) Repost SpamTechyInvestor01 2024-05-14 17:57:15
finally biocon came out of its resistance zone, might open gap up tommorow .
Login & Reply Like(0) Dislike(0) Repost Spamstocknews24 2022-09-09 19:02:13
Its usual price is at 390/.. ..Thismonth it will reach at least 340...
Login & Reply Like(0) Dislike(0) Repost SpamINVESTINGPOWER 2022-09-06 11:30:48
It continues to slide in-spite of the news flow, may be an opportunity to add.
Login & Reply Like(0) Dislike(0) Repost SpamOptionsTrade 2022-09-05 15:03:39
biocon 400 ce october expiry at Rs. 0.5 only.. target 3 to 4 (holding)
Login & Reply Like(0) Dislike(0) Repost SpamBrijesh01 2022-09-02 14:49:52
297 buy Oct fut biocon & hold for 320 with sl of 278
Login & Reply Like(0) Dislike(0) Repost SpamWorld_Investor1 2022-09-01 13:35:58
Biocon digest the fall today very well if anyone if fear of adani lower again can switch to biocon 302 level target 340 sl 296
Login & Reply Like(0) Dislike(0) Repost SpamPalkin 2022-08-28 17:49:16
USFDA looms over this company.. Monday it will dfntly go down
Login & Reply Like(0) Dislike(0) Repost Spam